Law firm cites Phospho-Soda package change
This article was originally published in The Tan Sheet
Executive Summary
The Laszlo & Associates law firm says C.B. Fleet Company has removed the "bowel cleanser" indication from the packaging for its nonprescription laxative after dozens of lawsuits were filed by people who suffered "acute renal failure and chronic kidney disease" after using the product as a bowel cleanser prior to colonoscopies and surgical procedures. In an Aug. 9 release, New York-based Laszlo says it is among the law firms representing clients from more than 20 states in suits against Lynchburg, Va.-based Fleet stemming from use of Phospho-Soda as a bowel cleanser. Following an FDA safety alert in May 2006, the firm recommended "follow the special instructions from your doctor exactly" when using its oral sodium phosphate products for bowel cleansing. FDA's announcement cited an association between bowel cleansers and acute phosphate nephropathy, a type of acute renal failure (1"The Tan Sheet" May 15, 2006, p. 10)...
You may also be interested in...
Church & Dwight Adds Minions To Vitamins, Bluetooth To Pregnancy Test
The household and personal care product firm also launches line extensions for its Vitafusion adult gummy vitamins promoted to benefit users' appearance, including products targeted for teens, and links to "the internet of things" to drive sales for its First Response pregnancy tests.
FDA Amends OTC Oral Sodium Phosphate Labeling, Warns Of Risks
FDA recommends consumers not use OTC oral sodium phosphate for bowel cleansing and says it will amend labeling for the products because of a risk of serious kidney injuries
Petition Urges FDA To Take Oral Sodium Phosphate Laxatives Off OTC Market
FDA should switch oral sodium phosphate bowel cleansers from over-the-counter to prescription status due to safety concerns or take them off the market altogether, according to a Sept. 20 citizen petition